CABA$1.41-1.15%
Cabaletta Bio, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$239.67M
Float & O/S:
Inst Own:
DilutionScan read 41 of Cabaletta Bio, Inc.'s SEC filings and found 2 warrant series, 2 ATM programs, 3 shelf registrations and 3 completed offerings on file for CABA. The latest dilution event on file is ATM sales on Aug 13, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
CABA
Going-concern warning, pre-revenue biotech
Snapshot
Cabaletta is a pre-revenue, clinical-stage biotech with no products on the market and a FY 2025 net loss of $167.9M. It holds $225.1M in cash but burns cash quickly, and Signal8 models roughly 14.1 months of runway.
What's Happening Right Now
- : Cabaletta disclosed on Sept 14, 2026 that warrants from its June 2025 offering expired, with about 51.3 million exercised for roughly $128.2M in proceeds, adding about 51 million new shares.
- : Cabaletta's 10-Q (filed Sept 9, 2026) states substantial doubt about its ability to continue as a going concern, with cash funding operations only into mid-2027 and a Q2 2026 net loss of $51.0M.
- : On Aug 13, 2026, Cabaletta reported a $51.0M Q2 2026 net loss and said its $225.1M cash position, boosted by a May 2026 offering, is expected to fund operations into mid-2027, while reaffirming mid-2027 myositis data and a planned second-half-2027 BLA filing.
